NVO
HealthcareNovo Nordisk A/S
$55.11
+$2.72 (+5.19%)
Jan 5, 2026
Price History (1Y)
Analysis
Novo Nordisk A/S is a multinational healthcare company based in Denmark. It operates within the drug manufacturers - general sector and has a significant presence globally with 78554 employees. The company's market capitalization stands at $244.88B, indicating its substantial scale. Financially, Novo Nordisk demonstrates strong profitability, with gross, operating, and profit margins of 83.4%, 44.4%, and 32.9% respectively. Returns on equity (ROE) and assets (ROA) are 71.5% and 21.1% respectively, suggesting efficient use of capital. The company's balance sheet shows a debt-to-equity ratio of 59.57, indicating manageable leverage. Cash reserves amount to $32.58B, while debt stands at $101.21B. The company's valuation is reflected in its price-to-earnings (P/E) ratio of 14.28, with forward P/E of 16.05 and a price-to-book of 9.20. The revenue growth rate over the past year has been 5.1%, while earnings growth was -26.5%. The company offers a dividend yield of 330.0% and payout ratio of 49.8%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Novo Nordisk A/S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Visit website →Key Statistics
- Market Cap
- $244.88B
- P/E Ratio
- 14.28
- 52-Week High
- $93.80
- 52-Week Low
- $43.08
- Avg Volume
- 16.94M
- Beta
- 0.36
- Dividend Yield
- 330.00%
Company Info
- Industry
- Drug Manufacturers - General
- Exchange
- NYQ
- Country
- Denmark
- Employees
- 78,554